Clinical Trials
Venetoclax Plus Quizartinib Combinations in Older Unfit AML Patients
Bergua et alJournal of Hematology & Oncology

The phase I/II prospective, open-label VEN-A-QUI trial evaluated the addition of the oral FLT3 inhibitor quizartinib to venetoclax combined with either azacitidine (VEN-AZA-Quiz) or low-dose cytarabine (VEN-LDAC-Quiz) in patients aged 60 years and older with newly diagnosed FLT3-ITD–positive or –negative acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy.
In the phase I dose-escalation cohorts (n = 14), the recommended phase II dose (RP2D) of quizartinib was determined to be 60 mg/day for the VEN-AZA-Quiz arm and 40 mg/day for the VEN-LDAC-Quiz arm. In phase II, 60 patients were randomized 1:1 to evaluate composite complete remission (CRc) rate as the primary endpoint. By Cycle 4, CRc was achieved in 18 of 31 patients (58.1%) receiving VEN-AZA-Quiz and 15 of 29 patients (51.7%) receiving VEN-LDAC-Quiz (p = 0.80). Median overall survival (OS) was 16.9 months for VEN-AZA-Quiz and 8.9 months for VEN-LDAC-Quiz (p = 0.81), with 3-year OS rates of 22.6% and 27.6%, respectively.
Subgroup analysis showed pronounced outcomes in FLT3-ITD–positive patients, who attained a 76.9% (10/13) CRc rate and a median OS of 29.3 months. Furthermore, median OS was 32 months for de novo AML versus 7.5 months for secondary AML (p < 0.001). The safety profile was characterized predominantly by infectious and hematologic toxicity, and the authors concluded that both triplet regimens demonstrated clinical activity with acceptable tolerability in older, chemotherapy-ineligible AML patients.
Key Takeaways
- In phase II, composite complete remission by Cycle 4 was achieved in 58.1% (18/31) of patients on venetoclax plus azacitidine and quizartinib compared with 51.7% (15/29) on venetoclax plus low-dose cytarabine and quizartinib (p = 0.80), with median overall survival of 16.9 months versus 8.9 months (p = 0.81).
- Patients with FLT3-ITD–positive disease achieved a composite complete remission rate of 76.9% (10/13) and a median overall survival of 29.3 months across regimens.
- Median overall survival reached 32 months in patients with de novo acute myeloid leukemia compared with 7.5 months in those with secondary disease (p < 0.001), with infectious and hematologic toxicities representing the most common adverse events.
Read the original sourceJournal of Hematology & Oncology
